These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15134483)

  • 21. How much do antiretroviral drugs penetrate into the central nervous system?
    Ene L; Duiculescu D; Ruta SM
    J Med Life; 2011 Nov; 4(4):432-9. PubMed ID: 22514580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents.
    Glynn SL; Yazdanian M
    J Pharm Sci; 1998 Mar; 87(3):306-10. PubMed ID: 9523983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.
    Calcagno A; Di Perri G; Bonora S
    Clin Pharmacokinet; 2014 Oct; 53(10):891-906. PubMed ID: 25200312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
    Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance-associated proteins: expression and function in the central nervous system.
    Dallas S; Miller DS; Bendayan R
    Pharmacol Rev; 2006 Jun; 58(2):140-61. PubMed ID: 16714484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Abgrall S; Le Bel J; Lele N; Laouénan C; Eychenne N; Mentré F; Peytavin G; Bouchaud O;
    HIV Clin Trials; 2013; 14(6):313-8. PubMed ID: 24334184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection.
    Ronaldson PT; Persidsky Y; Bendayan R
    Glia; 2008 Dec; 56(16):1711-35. PubMed ID: 18649402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Dahri K; Ensom MH
    Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
    Zink MC; Uhrlaub J; DeWitt J; Voelker T; Bullock B; Mankowski J; Tarwater P; Clements J; Barber S
    JAMA; 2005 Apr; 293(16):2003-11. PubMed ID: 15855434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of CNS transporters in the pharmacotherapy of HIV-1 associated neurological disorders.
    Ashraf T; Robillard K; Chan GN; Bendayan R
    Curr Pharm Des; 2014; 20(10):1543-63. PubMed ID: 23789949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-HIV nucleoside drugs: retrospective view at future].
    Kukhanova MK
    Mol Biol (Mosk); 2012; 46(6):860-73. PubMed ID: 23350232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug transporters relevant to HIV therapy.
    Thomas SA
    J HIV Ther; 2004 Nov; 9(4):92-6. PubMed ID: 15731741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.
    Bardsley-Elliot A; Perry CM
    Paediatr Drugs; 2000; 2(5):373-407. PubMed ID: 11022799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
    Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
    Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.
    Fiandra L; Capetti A; Sorrentino L; Corsi F
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):17-30. PubMed ID: 27832401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kryst J; Kawalec P; Pilc A
    PLoS One; 2015; 10(5):e0124279. PubMed ID: 25933004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.